IP Library Granted Patent US 10,487,346
Granted Patent B2
US 10,487,346 · App. 15/980,349 · Granted Nov 26, 2019

Biosynthesis of human milk oligosaccharides in engineered bacteria

Inventors: Massimo Merighi (Somerville, MA); John M. McCoy (Reading, MA); Matthew Ian Heidtman (Brighton, MA)
Assignee: Glycosyn LLC
C12P19/00C07H3/06C07H13/04C12N9/00C12N9/1051C12N9/14C12N9/2471C12N15/70C12P19/18C12P19/26C12Y204/01C12Y204/01065C12Y302/01023C12Y306/03018Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,487,346
App. No.
15/980,349
Granted
Nov 26, 2019
Kind
B2
Abstract

The invention provides compositions and methods for engineering bacteria to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.

Claims (29)

1. A method for producing a fucosylated oligosaccharide in a bacterium, comprising providing an isolated Escherichia coli ( E. coli ) bacterium comprising:

(i) an exogenous β-galactosidase having a detectable level of β-galactosidase activity that is reduced compared to that of a wild-type E. coli bacterium, wherein the level of β-galactosidase activity is between 0.05 and 200 units;

(ii) an inactivating mutation in a colanic acid synthesis gene; and

(iii) an exogenous fucosyltransferase gene,

culturing said bacterium in the presence of lactose; and

retrieving a fucosylated oligosaccharide from said bacterium or from a culture supernatant of said bacterium.

2. The method of claim 1 , wherein said colanic acid synthesis gene comprises an E. coli wcaJ, wzxC, wcaD, wza, wzb, or wzc gene.

3. The method of claim 2 , wherein said colanic acid synthesis gene comprises a wcaJ gene.

4. The method of claim 1 , comprising an increased intracellular guanosine diphosphate (GDP)-fucose level, wherein the increased intracellular GDP-fucose level is at least 10% more than the level of GDP-fucose in a wild-type bacterium.

5. The method of claim 1 , wherein said exogenous fucosyltransferase gene encodes an α(1,2) fucosyltransferase and/or an α(1,3) fucosyltransferase.

6. The method of claim 5 , wherein said α(1,2) fucosyltransferase gene comprises a Bacteroides fragilis wcfW gene.

7. The method of claim 5 , wherein said α(1,2) fucosyltransferase gene comprises a Helicobacter pylori 26695 futC gene.

8. The method of claim 1 , wherein said α(1,3) fucosyltransferase gene comprises a Helicobacter pylori 26695 futA gene.

9. The method of claim 1 , wherein said bacterium further comprises a functional lactose permease gene.

10. The method of claim 9 , wherein said lactose permease gene is an endogenous lactose permease gene.

11. The method of claim 9 , wherein said lactose permease gene comprises an E. coli lacY gene.

12. The method of claim 9 , wherein said lactose permease gene is an exogenous lactose permease gene.

13. The method of claim 1 , wherein said bacterium further comprises an exogenous E. coli rcsA or E. coli rcsB gene.

14. The method of claim 1 , wherein said bacterium further comprises an inactivating mutation in a lacA gene.

15. The method of claim 1 , wherein said bacterium further comprises an exogenous sialyltransferase gene.

16. The method of claim 15 wherein said exogenous sialyltransferase gene encodes an α(2,3) sialyltransferase.

17. The method of claim 1 , wherein said bacterium further comprises a deficient sialic acid catabolic pathway comprising a null mutation in an endogenous N-acetylneuraminate lyase gene or a null mutation in an endogenous N-acetylmannosamine kinase gene.

18. The method of claim 1 , wherein said bacterium further comprises an inactivating mutation in a lon gene.

19. The method of claim 1 , wherein said bacterium further comprises an increased intracellular lactose level, wherein the increased intracellular lactose level is at least 10% more than the level in a wild-type bacterium.

20. The method of claim 1 , wherein said bacterium further comprises an exogenous functional β-galactosidase gene that is inserted into an endogenous gene.

21. The method of claim 1 , wherein the level of β-galactosidase activity is between 0.05 and 5 units.

22. The method of claim 1 , wherein the level of β-galactosidase activity is between 0.05 and 4 units.

23. The method of claim 1 , wherein the level of β-galactosidase activity is between 0.05 and 3 units.

24. The method of claim 1 , wherein the level of β-galactosidase activity is between 0.05 and 2 units.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 6, 2025
From: MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, P.C.
To: GLYCOSYN, LLC
Reel/Frame 071338/0562 →
SECURITY INTEREST Recorded May 12, 2022
From: GLYCOSYN LLC; GLYCOSYN, INC.
To: GINKGO BIOWORKS, INC.
Reel/Frame 060052/0477 →
SECURITY INTEREST Recorded Feb 4, 2021
From: GLYCOSYN LLC
To: MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.
Reel/Frame 055148/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: MERIGHI, MASSIMO; MCCOY, JOHN M.; HEIDTMAN, MATTHEW IAN
To: GLYCOSYN LLC
Reel/Frame 049792/0803 →